Literature DB >> 36267507

Iron deficiency in patients of heart failure with reduced ejection fraction.

Balbir Singh1, Nitin Bajaj2, Priyanka Singh3, Arijit Kumar Ghosh4, R Anathakrishnan5, Navreet Singh2.   

Abstract

Background: Heart Failure with reduced Ejection Fraction (HFrEF) is a common disorder affecting a large population. Iron deficiency (ID) with and without anaemia is an important variable which is often underreported and under treated in clinical practice, which contributes to patient symptoms. The present study was undertaken to study the prevalence and Spectrum of Iron Deficiency in patients of HFrEF.
Methods: This is a single-centre observational study. All patients with a clinical diagnosis of HFrEF presenting to the hospital were studied. Ejection Fraction (EF) was assessed on Echo and ID was diagnosed on basis of serum ferritin <100 micro g/dl or serum ferritin 100-300 micro g/dl with low Transferrin Saturation (TSAT) (< 20%).
Results: We have studied a total of 204 patients with a predominantly male population (73%) and a mean age of 62.88 years. Most of our patients were in mid-level functional class (mean 2.48 ± 0.50) and had low EF (mean 29.56 ± 6.52). Out of 204 patients, 88.7% patients had ID with 83% patients having absolute ID. Of the total patients with HF, 70% had anaemia. Amongst those with anaemia 93% had ID, and even without anaemia, 68% had absolute or functional ID, underlying the importance of evaluating iron status in all patients of HF irrespective of their haemoglobin levels.
Conclusion: This study highlights the burden of iron deficiency in heart failure patients in the Indian population and opens the way for large scale studies for better characterization of iron deficiency as well as therapeutic trials in the management of heart failure patients.
© 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Absolute iron deficiency; Functional iron deficiency; Heart failure with reduced ejection fraction

Year:  2022        PMID: 36267507      PMCID: PMC9577345          DOI: 10.1016/j.mjafi.2022.04.013

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  23 in total

1.  Iron Status in Chronic Heart Failure: Impact on Symptoms, Functional Class and Submaximal Exercise Capacity.

Authors:  Cristina Enjuanes; Jordi Bruguera; María Grau; Mercé Cladellas; Gina Gonzalez; Oona Meroño; Pedro Moliner-Borja; José M Verdú; Nuria Farré; Josep Comín-Colet
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2015-12-10

2.  Iron deficiency and red cell indices in patients with heart failure.

Authors:  Michał Tkaczyszyn; Josep Comín-Colet; Adriaan A Voors; Dirk J van Veldhuisen; Cristina Enjuanes; Pedro Moliner-Borja; Piotr Rozentryt; Lech Poloński; Waldemar Banasiak; Piotr Ponikowski; Peter van der Meer; Ewa A Jankowska
Journal:  Eur J Heart Fail       Date:  2017-04-06       Impact factor: 15.534

Review 3.  Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Authors:  Stefan D Anker; Bridget-Anne Kirwan; Dirk J van Veldhuisen; Gerasimos Filippatos; Josep Comin-Colet; Frank Ruschitzka; Thomas F Lüscher; Gregory P Arutyunov; Michael Motro; Claudio Mori; Bernard Roubert; Stuart J Pocock; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2017-04-24       Impact factor: 15.534

4.  Iron deficiency in chronic heart failure: an international pooled analysis.

Authors:  Ijsbrand T Klip; Josep Comin-Colet; Adriaan A Voors; Piotr Ponikowski; Cristina Enjuanes; Waldemar Banasiak; Dirk J Lok; Piotr Rosentryt; Ainhoa Torrens; Lech Polonski; Dirk J van Veldhuisen; Peter van der Meer; Ewa A Jankowska
Journal:  Am Heart J       Date:  2013-02-22       Impact factor: 4.749

5.  Adaptive response of the heart to long-term anemia induced by iron deficiency.

Authors:  Yoshiro Naito; Takeshi Tsujino; Mika Matsumoto; Tsuyoshi Sakoda; Mitsumasa Ohyanagi; Tohru Masuyama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-09       Impact factor: 4.733

6.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

7.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.

Authors:  Piotr Ponikowski; Dirk J van Veldhuisen; Josep Comin-Colet; Georg Ertl; Michel Komajda; Viacheslav Mareev; Theresa McDonagh; Alexander Parkhomenko; Luigi Tavazzi; Victoria Levesque; Claudio Mori; Bernard Roubert; Gerasimos Filippatos; Frank Ruschitzka; Stefan D Anker
Journal:  Eur Heart J       Date:  2014-08-31       Impact factor: 29.983

8.  Prevalence and spectrum of iron deficiency in heart failure patients in south Rajasthan.

Authors:  Sohan Kumar Sharma; Shalabh Kumar Agarwal; Kapil Bhargava; Mukesh Sharma; Karan Chopra; Gopinath Arumugam
Journal:  Indian Heart J       Date:  2016-01-11

9.  Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study.

Authors:  James M Beattie; Rani Khatib; Ceri J Phillips; Simon G Williams
Journal:  Open Heart       Date:  2020-03-11

10.  Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.

Authors:  Gregory D Lewis; Rajeev Malhotra; Adrian F Hernandez; Steven E McNulty; Andrew Smith; G Michael Felker; W H Wilson Tang; Shane J LaRue; Margaret M Redfield; Marc J Semigran; Michael M Givertz; Peter Van Buren; David Whellan; Kevin J Anstrom; Monica R Shah; Patrice Desvigne-Nickens; Javed Butler; Eugene Braunwald
Journal:  JAMA       Date:  2017-05-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.